The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

George I. Papakostas, Timothy Petersen, Barry D. Lebowitz, David Mischoulon, Julie L. Ryan, Andrew A. Nierenberg, Teodoro Bottiglieri, Jonathan E. Alpert, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

The objective of the present study was to examine the relationship between serum folate, vitamin B12, and homocysteine levels and the timing of clinical improvement to fluoxetine in major depressive disorder (MDD) patients. A total of 110 outpatients with MDD who responded to an 8-wk trial of fluoxetine had serum folate, B12, and homocysteine measurements at baseline (prior to fluoxetine initiation). Onset of clinical improvement was defined as a 30% decrease in Hamilton Depression Scale scores that led to a 50% decrease by week 8. Patients with low folate levels (≤2.5 ng/ml) were more likely to experience a later onset of clinical improvement than eufolatemic patients (p=0.0028). B12 and homocysteine level status did not predict time to clinical improvement (p>0.05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk.

Original languageEnglish (US)
Pages (from-to)523-528
Number of pages6
JournalInternational Journal of Neuropsychopharmacology
Volume8
Issue number4
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Fluoxetine
Major Depressive Disorder
Homocysteine
Vitamin B 12
Folic Acid
Serum
Outpatients
Depression
Therapeutics

Keywords

  • Fluoxetine
  • Folate
  • Homocysteine
  • Onset
  • Response
  • Vitamin B12

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. / Papakostas, George I.; Petersen, Timothy; Lebowitz, Barry D.; Mischoulon, David; Ryan, Julie L.; Nierenberg, Andrew A.; Bottiglieri, Teodoro; Alpert, Jonathan E.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: International Journal of Neuropsychopharmacology, Vol. 8, No. 4, 12.2005, p. 523-528.

Research output: Contribution to journalArticle

Papakostas, George I. ; Petersen, Timothy ; Lebowitz, Barry D. ; Mischoulon, David ; Ryan, Julie L. ; Nierenberg, Andrew A. ; Bottiglieri, Teodoro ; Alpert, Jonathan E. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. In: International Journal of Neuropsychopharmacology. 2005 ; Vol. 8, No. 4. pp. 523-528.
@article{1a82354540b548e08d2d84da10e17c15,
title = "The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine",
abstract = "The objective of the present study was to examine the relationship between serum folate, vitamin B12, and homocysteine levels and the timing of clinical improvement to fluoxetine in major depressive disorder (MDD) patients. A total of 110 outpatients with MDD who responded to an 8-wk trial of fluoxetine had serum folate, B12, and homocysteine measurements at baseline (prior to fluoxetine initiation). Onset of clinical improvement was defined as a 30{\%} decrease in Hamilton Depression Scale scores that led to a 50{\%} decrease by week 8. Patients with low folate levels (≤2.5 ng/ml) were more likely to experience a later onset of clinical improvement than eufolatemic patients (p=0.0028). B12 and homocysteine level status did not predict time to clinical improvement (p>0.05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk.",
keywords = "Fluoxetine, Folate, Homocysteine, Onset, Response, Vitamin B12",
author = "Papakostas, {George I.} and Timothy Petersen and Lebowitz, {Barry D.} and David Mischoulon and Ryan, {Julie L.} and Nierenberg, {Andrew A.} and Teodoro Bottiglieri and Alpert, {Jonathan E.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "2005",
month = "12",
doi = "10.1017/S1461145705005195",
language = "English (US)",
volume = "8",
pages = "523--528",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "4",

}

TY - JOUR

T1 - The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Lebowitz, Barry D.

AU - Mischoulon, David

AU - Ryan, Julie L.

AU - Nierenberg, Andrew A.

AU - Bottiglieri, Teodoro

AU - Alpert, Jonathan E.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 2005/12

Y1 - 2005/12

N2 - The objective of the present study was to examine the relationship between serum folate, vitamin B12, and homocysteine levels and the timing of clinical improvement to fluoxetine in major depressive disorder (MDD) patients. A total of 110 outpatients with MDD who responded to an 8-wk trial of fluoxetine had serum folate, B12, and homocysteine measurements at baseline (prior to fluoxetine initiation). Onset of clinical improvement was defined as a 30% decrease in Hamilton Depression Scale scores that led to a 50% decrease by week 8. Patients with low folate levels (≤2.5 ng/ml) were more likely to experience a later onset of clinical improvement than eufolatemic patients (p=0.0028). B12 and homocysteine level status did not predict time to clinical improvement (p>0.05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk.

AB - The objective of the present study was to examine the relationship between serum folate, vitamin B12, and homocysteine levels and the timing of clinical improvement to fluoxetine in major depressive disorder (MDD) patients. A total of 110 outpatients with MDD who responded to an 8-wk trial of fluoxetine had serum folate, B12, and homocysteine measurements at baseline (prior to fluoxetine initiation). Onset of clinical improvement was defined as a 30% decrease in Hamilton Depression Scale scores that led to a 50% decrease by week 8. Patients with low folate levels (≤2.5 ng/ml) were more likely to experience a later onset of clinical improvement than eufolatemic patients (p=0.0028). B12 and homocysteine level status did not predict time to clinical improvement (p>0.05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk.

KW - Fluoxetine

KW - Folate

KW - Homocysteine

KW - Onset

KW - Response

KW - Vitamin B12

UR - http://www.scopus.com/inward/record.url?scp=25644442845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644442845&partnerID=8YFLogxK

U2 - 10.1017/S1461145705005195

DO - 10.1017/S1461145705005195

M3 - Article

VL - 8

SP - 523

EP - 528

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 4

ER -